Form 4: Revvity CCO Miriame Reports Equity Transactions

Revvity's Chief Commercial Officer, Victor Miriame, reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.

Summary

• Victor Miriame, Senior Vice President and Chief Commercial Officer of Revvity, Inc. (RVTY), reported several transactions on February 4, 2026.
• Miriame disposed of 536 shares of common stock at a price of $101.13 per share to satisfy tax withholding obligations upon the vesting of restricted stock units originally granted on February 4, 2025.
• Following this disposition, Miriame beneficially owned 13,752 shares of common stock.
• Miriame acquired 5,401 shares of common stock in the form of time-based restricted stock units (RSUs) at a price of $0 per share.
• These new RSUs are scheduled to vest in three equal annual installments, beginning on the first anniversary of the grant date.
• Following this acquisition, Miriame beneficially owned 19,153 shares of common stock.
• Miriame also acquired 15,449 Non-Qualified (NQ) Stock Options, with a conversion or exercise price of $103.395 per share.
• These stock options are scheduled to vest in three equal annual installments, beginning on the first anniversary of the grant date, and have an expiration date of February 4, 2033.
• The filing also corrected an administrative error in the vesting schedule for a restricted stock unit grant reported in a Form 4 filed on February 6, 2025, clarifying that it vests in three equal annual installments starting on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. It reflects routine executive compensation and alignment of interests, with no significant new information to materially alter the investment thesis.

Positives

• The acquisition of 5,401 restricted stock units and 15,449 NQ stock options aligns the Chief Commercial Officer's long-term interests with those of shareholders.
• The equity grants serve as a form of executive compensation, incentivizing performance and retention.

Negatives

• The disposition of 536 shares for tax withholding, while a standard practice upon RSU vesting, reduces the direct shareholding of the executive.

Future Outlook

The newly acquired restricted stock units and NQ stock options are scheduled to vest in three equal annual installments, beginning on the first anniversary of their grant date (February 4, 2026), indicating a future alignment of executive compensation with long-term company performance.

Industry Context

StockSavvy.ai notes that executive equity grants, including restricted stock units and stock options, are a common component of compensation packages across the life sciences and diagnostics industry. These grants are designed to align the interests of key executives with those of shareholders by tying a significant portion of their compensation to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• Executive compensation structures in the life sciences sector, including companies like Thermo Fisher Scientific (TMO) or Danaher Corporation (DHR), frequently utilize a mix of base salary, annual cash incentives, and long-term equity awards (RSUs, stock options) to attract and retain top talent.
• The vesting schedule of three equal annual installments is a standard practice, similar to equity compensation plans observed at peers such as PerkinElmer (PKI) before its spin-off, or Agilent Technologies (A) for its senior leadership.
• The disposition of shares to cover tax withholding upon RSU vesting is a routine and expected event, consistent with practices across publicly traded companies globally to manage tax liabilities associated with equity compensation.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Commercial Officer's financial interests with long-term shareholder value creation, potentially incentivizing stronger performance.
• Employees: The compensation structure for a senior executive can set a precedent or reflect the company's overall approach to rewarding key talent.

Next Steps

• The newly acquired restricted stock units and NQ stock options will begin vesting in three equal annual installments starting on February 4, 2027 (the first anniversary of the grant date).

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and tax-related transactions. It does not contain information that would fundamentally alter the investment outlook for Revvity, Inc. While the grants align executive interests with shareholders, they are expected events and do not provide new insights into the company's operational performance or strategic direction that would warrant a change in recommendation based solely on this filing.

Keywords

Revvity, RVTY, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant, Tax Withholding